乳果糖治疗肝硬化、门静脉高压及患者报告结局不佳的患者:Mi-Kristal 试验
Mi-Kristal 试验将 52 例肝硬化、门静脉高压、无肝性脑病史且因肝硬化导致工作生产力与活动受损评分高的患者随机分入结晶乳果糖组(20 g 每日两次)或无肝性脑病导向治疗组,疗程 28 天。主要终点整体健康相关生活质量(Short Form-8)无改善,但乳果糖组动物命名测试评分、睡眠质量和活动受损均有改善。
要点
- 乳果糖 20 g 每日两次治疗 28 天未改善整体健康相关生活质量。
- 乳果糖组动物命名测试评分升高 3.7(95%CI 2.1-5.4),对照组为 0.2(95%CI -1.7-1.4)。
- 乳果糖组报告睡眠良好者占 92%,对照组占 52%(P=0.001)。
核心结论
- 乳果糖改善患者报告结局不佳的肝硬化患者的睡眠和活动受损。
- 使用 Short Form-8 健康调查工具评估,28 天后未观察到整体健康相关生活质量的改善。
研究设计与样本
- 28 天随机试验,比较结晶乳果糖 20 g 每日两次与无肝性脑病导向治疗。
- 纳入 52 例肝硬化、门静脉高压、无肝性脑病史且因肝硬化导致工作生产力与活动受损评分(0-10)高的患者。
主要发现
- 主要终点整体健康相关生活质量:乳果糖组增加 8.1 分(95%CI 3.7-12.4),对照组增加 6.6 分(95%CI 2.3-10.8),P=0.6。
- 动物命名测试评分:乳果糖组增加 3.7(95%CI 2.1-5.4),对照组增加 0.2(95%CI -1.7-1.4),P=0.002。
- 睡眠良好者比例:乳果糖组 92% vs 对照组 52%,P=0.001。
- 活动受损评分:乳果糖组 3.0 vs 对照组 4.8,P=0.02。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Poor patient-reported outcomes (PROs) are common in cirrhosis, including poor sleep and health-related quality of life (HRQOL). HE is a major driver of poor PROs. Many clinicians initiate lactulose therapy to address poor PROs. PRO-triggered therapy, however, has not been studied till date. METHODS: We conducted a 28-day randomized trial of crystalline lactulose therapy (20 g BID) compared with no HE-directed therapy in 52 patients with cirrhosis, portal hypertension, no prior HE, and high Work Productivity and Activity Impairment scores (0-10) attributed to cirrhosis. The primary outcome was change in global HRQOL measured with Short Form-8 Health Survey. Secondary outcomes included change in Animal Naming Test score, Work Productivity and Activity Impairment, and sleep quality (scored "very bad" to "very good"). APPROACH AND RESULTS: Overall, 52 patients underwent randomization; 3 subjects withdrew from the crystalline lactulose arm (1 before medication initiation, 1 due to an unrelated condition, and 1 due to high baseline bowel movements). The average age was 60 years, the average Model for Endstage Liver Disease-Sodium score was 10.5, and 56% of the patients had ascites. Baseline bowel movements were 2.3/day, with 35% of the patients having Bristol Stool Scale >4. At 28 days, there was no improvement in HRQOL: patients receiving crystalline lactulose had an 8.1-point (95% CI: 3.7-12.4) increase compared with 6.6 (95% CI: 2.3-10.8) in the control group ( p = 0.6). Lactulose was associated with a significantly ( p = 0.002) increased Animal Naming Test score (3.7, 95% CI: 2.1-5.4) versus the control group (0.2, 95% CI: -1.7, 1.4). Lactulose users reported more good sleep (92% vs. 52%, p = 0.001) and lower activity impairment (3.0 vs. 4.8, p = 0.02). CONCLUSIONS: Lactulose improves sleep and activity impairment in patients with poor PROs. We did not observe any improvement in global HRQOL after 28 days using the Short Form-8 Health Survey instrument.
引用
- Tapper EB, Ospina E, Salim N, et al. Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: The Mi-Kristal trial. Hepatology. 2023. PMID: 37066820. doi:10.1097/HEP.0000000000000408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。